IE70455B1 - Pasteurized glue for joining human or animal tissues - Google Patents
Pasteurized glue for joining human or animal tissuesInfo
- Publication number
- IE70455B1 IE70455B1 IE276690A IE276690A IE70455B1 IE 70455 B1 IE70455 B1 IE 70455B1 IE 276690 A IE276690 A IE 276690A IE 276690 A IE276690 A IE 276690A IE 70455 B1 IE70455 B1 IE 70455B1
- Authority
- IE
- Ireland
- Prior art keywords
- mixture
- process according
- pasteurization
- proteins
- pasteurized
- Prior art date
Links
- 239000003292 glue Substances 0.000 title claims description 9
- 241001465754 Metazoa Species 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 26
- 238000009928 pasteurization Methods 0.000 claims abstract description 22
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 17
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 17
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 17
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims description 10
- 150000005846 sugar alcohols Chemical class 0.000 claims description 9
- 108010071289 Factor XIII Proteins 0.000 claims description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229940012444 factor xiii Drugs 0.000 claims description 8
- 229960002897 heparin Drugs 0.000 claims description 8
- 229920000669 heparin Polymers 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 2
- 239000002874 hemostatic agent Substances 0.000 claims description 2
- 239000003868 thrombin inhibitor Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 abstract description 2
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012460 protein solution Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 108010039627 Aprotinin Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 229940038773 trisodium citrate Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- -1 glycine and arginine Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8910355A FR2650508A1 (fr) | 1989-08-01 | 1989-08-01 | Colle pasteurisee pour reunir des tissus humain ou animal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE902766A1 IE902766A1 (en) | 1991-02-27 |
| IE70455B1 true IE70455B1 (en) | 1997-02-26 |
Family
ID=9384356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE276690A IE70455B1 (en) | 1989-08-01 | 1990-07-31 | Pasteurized glue for joining human or animal tissues |
Country Status (9)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0534178B1 (en) * | 1991-09-27 | 2001-04-18 | Omrix Biopharmaceuticals S.A. | Improved tissue glue prepared by using cryoprecipitate |
| CZ280540B6 (cs) * | 1991-09-27 | 1996-02-14 | Opperbas Holding B.V. | Tkáňové lepidlo obsahující kryoprecipitát, způsob jeho výroby a použití aprotininu, proteázy z hadího jedu a batroxobinu pro jeho přípravu |
| DE4202667C1 (enrdf_load_stackoverflow) * | 1992-01-29 | 1993-05-13 | Behringwerke Ag, 3550 Marburg, De | |
| FR2687317B1 (fr) * | 1992-02-13 | 1995-06-23 | Aetsrn | Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique. |
| RU2139735C1 (ru) * | 1998-09-28 | 1999-10-20 | Мустафин Айрат Харисович | Способ получения материала для укрытия раневой поверхности печени |
| AU2005295368B2 (en) | 2004-10-20 | 2011-06-09 | Ethicon, Inc. | A reinforced absorbable multilayered hemostatic wound dressing and method of making |
| US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6029687B2 (ja) | 1978-11-07 | 1985-07-12 | 株式会社ミドリ十字 | ヒト胎盤由来血液凝固第１０３因子の濃縮液の製造方法 |
| DE2916711A1 (de) * | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| DE3176491D1 (en) | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
| JPS56135418A (en) * | 1980-03-27 | 1981-10-22 | Green Cross Corp:The | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human |
| DE3230849A1 (de) * | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung |
| AT390001B (de) * | 1984-09-28 | 1990-03-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
-
1989
- 1989-08-01 FR FR8910355A patent/FR2650508A1/fr active Granted
-
1990
- 1990-07-31 ES ES90912569T patent/ES2080155T3/es not_active Expired - Lifetime
- 1990-07-31 IE IE276690A patent/IE70455B1/en not_active IP Right Cessation
- 1990-07-31 PT PT94859A patent/PT94859B/pt not_active IP Right Cessation
- 1990-07-31 WO PCT/FR1990/000577 patent/WO1991001762A1/fr active IP Right Grant
- 1990-07-31 AT AT90912569T patent/ATE129903T1/de not_active IP Right Cessation
- 1990-07-31 EP EP90912569A patent/EP0436712B1/fr not_active Expired - Lifetime
- 1990-07-31 DK DK90912569.2T patent/DK0436712T3/da active
- 1990-07-31 DE DE69023470T patent/DE69023470T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991001762A1 (fr) | 1991-02-21 |
| IE902766A1 (en) | 1991-02-27 |
| DK0436712T3 (da) | 1996-01-22 |
| EP0436712B1 (fr) | 1995-11-08 |
| ATE129903T1 (de) | 1995-11-15 |
| FR2650508A1 (fr) | 1991-02-08 |
| EP0436712A1 (fr) | 1991-07-17 |
| DE69023470T2 (de) | 1996-05-02 |
| DE69023470D1 (de) | 1995-12-14 |
| FR2650508B1 (enrdf_load_stackoverflow) | 1994-08-19 |
| PT94859B (pt) | 1997-07-31 |
| ES2080155T3 (es) | 1996-02-01 |
| PT94859A (pt) | 1991-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5260420A (en) | Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof | |
| EP1151007B1 (en) | A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method | |
| US5151499A (en) | Production method for protein-containing composition | |
| JP2787317B2 (ja) | トロンビン凝固性蛋白質の濃縮物、その製造方法及びその治療的用途 | |
| US8741846B2 (en) | Storage-stable, functionally intact fibrinogen | |
| KR20040015692A (ko) | 저장 안정성의 액상 피브리노겐 제형 | |
| US4085095A (en) | Clottable fibrinogen free Factor VIII product and process | |
| US4562072A (en) | Process for the pasteurization of antihemophilic cryoprecipitate (AHC) and antihemophilic cryoprecipitate prepared thereby | |
| US4579735A (en) | Process for the pasteurization of human residual plasma | |
| HUT67051A (en) | Improved tissue glue prepared by using cryoprecipitate | |
| PL174098B1 (pl) | Kompozycja stabilizująca osocze krwi podczas pasteryzacji i sposób pasteryzacji osocza krwi | |
| IE70455B1 (en) | Pasteurized glue for joining human or animal tissues | |
| ATE233576T1 (de) | Wärmebehandlung von blutplasmaproteinen | |
| FI96918C (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
| EP0401232B1 (en) | A process for pasteurization of aqueous solutions of factor viii | |
| EP1057490A2 (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition | |
| CA2228031A1 (en) | Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom and method for their production | |
| MXPA00004085A (en) | Use of tranexamic acid for the preparation of a human fibrinogen composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |